Disease severity as a predictor of outcome in scleroderma

Lancet

Volumn 359, Issue 9303, 2002, Pages 277-279

  Gelber, Allan C ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENICILLAMINE; PROSTACYCLIN; PROTON PUMP INHIBITOR; VASODILATOR AGENT;

ANTIBODY SPECIFICITY; AUTOIMMUNITY; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FIBROSIS; GASTROINTESTINAL REFLUX; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; KIDNEY FUNCTION; LUNG ALVEOLITIS; LUNG FUNCTION; MORTALITY; NOTE; ONSET AGE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RISK BENEFIT ANALYSIS; SCLERODERMA; SCORING SYSTEM; SKINFOLD; STEM CELL TRANSPLANTATION; TARGET ORGAN; VASCULAR DISEASE;

EID: 0037176536     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07535-9     Document Type: Note

References (11)

1. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit
2. Severe organ involvement in systemic sclerosis with diffuse scleroderma
3. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade
4. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study
5. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
6. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
7. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
8. A phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
9. Assessment of damage and activity in systemic sclerosis
10. A disease severity scale for systemic sclerosis: Development and testing
11. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: Using a modified Medsger scale